icon-folder.gif   Conference Reports for NATAP  
 
 

16thEuro

Back grey_arrow_rt.gif
 
 
 
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Results From the SWORD-1 and SWORD-2 Studies
 
 
  Reported by Jules Levin
16th European AIDS Conference; October 25-27, 2017; Milan, Italy
 
Alan Oglesby,1Yogesh Punekar,2Kostas Angelis,3Antonio Antela,4Michael Aboud,2Elizabeth Blair,1Lesley Kahl,2Martin Gartland,1Brian Wynne,5Miranda Murray2 1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Brentford, UK; 3GlaxoSmithKline, Uxbridge, UK; 4Infectious Diseases Unit, Hospital Clinico de Santiago, La Coruna, Spain; 5ViiV Healthcare, Collegeville, PA, USA

AASDL1

AASDL2

AASDL3

AASDL4